Susquehanna International Group
CBIO

Susquehanna International Group’s Crescent Biopharma CBIO Stock Holding History

Susquehanna International Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,161
Closed -$348K – 12467
2024
Q1 		$348K Buy
1,161
+989
+575% +$295K ﹤0.01% 9359
2023
Q4 		$40.6K Sell
172
-35
-17% -$5.44K ﹤0.01% 11793
2023
Q3 		$31.1K Sell
207
-201
-49% -$31.7K ﹤0.01% 11475
2023
Q2 		$71K Buy
408
+183
+81% +$30.7K ﹤0.01% 11173
2023
Q1 		$28.4K Buy
+225
New +$50.6K ﹤0.01% 11936
2022
Q1 		– Sell
-2,465
Closed -$355K – 13366
2021
Q4 		$355K Buy
2,465
+256
+12% +$46.5K ﹤0.01% 10078
2021
Q3 		$484K Sell
2,209
-727
-25% -$154K ﹤0.01% 9479
2021
Q2 		$681K Buy
2,936
+902
+44% +$230K ﹤0.01% 8813
2021
Q1 		$612K Buy
2,034
+786
+63% +$282K ﹤0.01% 9011
2020
Q4 		$469K Buy
1,248
+685
+122% +$240K ﹤0.01% 8423
2020
Q3 		$173K Sell
563
-84
-13% -$32.1K ﹤0.01% 9586
2020
Q2 		$243K Buy
+647
New +$183K ﹤0.01% 8704
2019
Q3 		– Sell
-118
Closed -$141K – 10403
2019
Q2 		$141K Sell
118
-38
-24% -$45.4K ﹤0.01% 9417
2019
Q1 		$194K Buy
+156
New +$179K ﹤0.01% 7898
2018
Q4 		– Sell
-124
Closed -$179K – 9297
2018
Q3 		$179K Sell
124
-142
-53% -$215K ﹤0.01% 8304
2018
Q2 		$429K Sell
266
-313
-54% -$538K ﹤0.01% 7104
2018
Q1 		$940K Sell
579
-730
-56% -$1.52M ﹤0.01% 5369
2017
Q4 		$2.2M Buy
1,309
+1,172
+855% +$1.55M ﹤0.01% 3740
2017
Q3 		$192K Sell
137
-862
-86% -$1.01M ﹤0.01% 8043
2017
Q2 		$1.11M Buy
+999
New +$825K ﹤0.01% 5028

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's CBIO Position: Q1 2026 in Review

Susquehanna International Group increased its Crescent Biopharma (CBIO) stake by 274% in Q1 2026, buying an estimated $1.8M and bringing the position to 213,635 shares worth $3.92M. The position accounts for ﹤0.01% of the portfolio, ranked #4707.

Susquehanna International Group first reported a position in CBIO in Q2 2017 and has held it in 26 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Susquehanna International Group held 213,635 shares of Crescent Biopharma worth $3.92M as of Q1 2026.
  • Susquehanna International Group bought 156,587 Crescent Biopharma shares in Q1 2026, an estimated $1.8M.
  • Crescent Biopharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4707 holding.
  • Susquehanna International Group first reported a position in Crescent Biopharma in Q2 2017 and has held it in 26 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.